{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:28:56Z","timestamp":1794457736325,"version":"4.9.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejogrb.2026.115499","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:14:57Z","timestamp":1792106097000},"page":"115499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The effect of glucagon-like peptide-1 receptor agonists versus metformin on pregnancy rates in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized trials"],"prefix":"10.1016","volume":"327","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-9258","authenticated-orcid":false,"given":"Emre","family":"Kar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4195-4922","authenticated-orcid":false,"given":"John","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3156-2527","authenticated-orcid":false,"given":"Mehtap Ak\u0131n","family":"Efe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hale G\u00f6ksever","family":"\u00c7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcrkan","family":"Bozda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0810-6195","authenticated-orcid":false,"given":"Ercan","family":"Ba\u015ftu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejogrb.2026.115499_b0005","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/humupd\/dmy022","article-title":"Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"24","author":"Skiba","year":"2018","journal-title":"Hum Reprod Update"},{"issue":"9","key":"10.1016\/j.ejogrb.2026.115499_b0010","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/humrep\/dey256","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"33","author":"Teede","year":"2018","journal-title":"Hum Reprod Oxf Engl"},{"issue":"5","key":"10.1016\/j.ejogrb.2026.115499_b0015","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1210\/er.2015-1104","article-title":"The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited","volume":"37","author":"Rosenfield","year":"2016","journal-title":"Endocr Rev"},{"issue":"7","key":"10.1016\/j.ejogrb.2026.115499_b0020","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1210\/jc.2002-021545","article-title":"Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes","volume":"88","author":"Kolterman","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ejogrb.2026.115499_b0025","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"11","key":"10.1016\/j.ejogrb.2026.115499_b0030","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejogrb.2026.115499_b0035","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"J Am Med Assoc"},{"issue":"10295","key":"10.1016\/j.ejogrb.2026.115499_b0040","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115499_b0045","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch","year":"2022","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115499_b0050","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1210\/jc.2015-3780","article-title":"Perspectives in polycystic ovary syndrome: from hair to eternity","volume":"101","author":"Dunaif","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2026.115499_b0055","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.ejogrb.2026.115499_b0060","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejogrb.2026.115499_b0065","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.ejogrb.2026.115499_b0070","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ejogrb.2026.115499_b0075","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/cen.13454","article-title":"Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome","volume":"87","author":"Liu","year":"2017","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115499_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-18-0175","article-title":"Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study","volume":"179","author":"Salamun","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.ejogrb.2026.115499_b0085","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00404-022-06700-3","article-title":"Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT","volume":"306","author":"Li","year":"2022","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115499_b0090","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12958-025-01447-3","article-title":"Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight\/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial","volume":"23","author":"Chen","year":"2025","journal-title":"Reprod Biol Endocrinol RBE"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115499_b0095","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12902-023-01497-x","article-title":"Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis","volume":"23","author":"Hu","year":"2023","journal-title":"BMC Endocr Disord"},{"issue":"7","key":"10.1016\/j.ejogrb.2026.115499_b0100","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","author":"Elkind-Hirsch","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ejogrb.2026.115499_b0105","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s43032-023-01222-y","article-title":"The effectiveness and safety of exenatide versus metformin in patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials","volume":"30","author":"Ye","year":"2023","journal-title":"Reprod Sci"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115499_b0110","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12902-023-01500-5","article-title":"Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115499_b0115","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12905-025-03787-z","article-title":"The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis","volume":"25","author":"Huang","year":"2025","journal-title":"BMC Womens Health"},{"issue":"4","key":"10.1016\/j.ejogrb.2026.115499_b0120","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1210\/er.2009-0002","article-title":"Endocrine-disrupting chemicals: an endocrine society scientific statement","volume":"30","author":"Diamanti-Kandarakis","year":"2009","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.ejogrb.2026.115499_b0125","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1210\/er.2015-1018","article-title":"Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome","volume":"36","author":"Dumesic","year":"2015","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115499_b0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13048-025-01621-6","article-title":"Physiopathology of polycystic ovary syndrome in endocrinology, metabolism and inflammation","volume":"18","author":"Su","year":"2025","journal-title":"J Ovarian Res"},{"issue":"13","key":"10.1016\/j.ejogrb.2026.115499_b0135","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199509283331307","article-title":"Polycystic ovary syndrome","volume":"333","author":"Franks","year":"1995","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115499_b0140","doi-asserted-by":"crossref","first-page":"16512","DOI":"10.1038\/s41598-025-99622-4","article-title":"Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials","volume":"15","author":"Lin","year":"2025","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115499_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2010.11.036","article-title":"Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis","volume":"95","author":"Escobar-Morreale","year":"2011","journal-title":"Fertil Steril"},{"issue":"14","key":"10.1016\/j.ejogrb.2026.115499_b0150","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"J Am Med Assoc"},{"issue":"7","key":"10.1016\/j.ejogrb.2026.115499_b0155","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/dom.15620","article-title":"Effect of semaglutide 2.4\u2009mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: patient-reported outcomes from the STEP 1-4 trials","volume":"26","author":"Rubino","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.ejogrb.2026.115499_b0160","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.fertnstert.2023.07.025","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"120","author":"Teede","year":"2023","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.ejogrb.2026.115499_b0165","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/humrep\/dex044","article-title":"High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"32","author":"Cooney","year":"2017","journal-title":"Hum Reprod"},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115499_b0170","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4103\/IJPSYM.IJPSYM_561_17","article-title":"Anxiety, depression, and quality of life in women with polycystic ovarian syndrome","volume":"40","author":"Chaudhari","year":"2018","journal-title":"Indian J Psychol Med"},{"issue":"5","key":"10.1016\/j.ejogrb.2026.115499_b0175","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.fertnstert.2018.01.038","article-title":"Androgen excess- polycystic ovary syndrome society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome","volume":"109","author":"Dokras","year":"2018","journal-title":"Fertil Steril"},{"issue":"4","key":"10.1016\/j.ejogrb.2026.115499_b0180","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70021","article-title":"Pregnancy outcomes after semaglutide exposure","volume":"136","author":"Kolding","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115499_b0185","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy","volume":"184","author":"Cesta","year":"2024","journal-title":"JAMA Intern Med"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211526005671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211526005671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:48:17Z","timestamp":1794455297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211526005671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":37,"alternative-id":["S0301211526005671"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2026.115499","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of glucagon-like peptide-1 receptor agonists versus metformin on pregnancy rates in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2026.115499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115499"}}